Scheriproct Suppositories 1.3 mg/1 mg Suppository

Short term (5 u2013 7 days) symptomatic relief of perianal discomfort, inflammation and itching caused by thrombosed haemorrhoids, anal fissure and pruritus ani.

Posology
The anal region should be cleaned thoroughly before using SCHERIPROCT SUPPOSITORIES, which is best inserted after defaecation. Unless otherwise prescribed by the doctor, generally insert one suppository daily high into the rectum. If symptoms are severe, insert one suppository two to three times on the first day.
There is usually a rapid improvement, but this should not mislead one into stopping treatment too soon.

• Hypersensitivity to prednisolone hexanoate, cinchocaine hydrochloride or to any of the other excipients of SCHERIPROCT SUPPOSITORIES.
• Viral infections, primary bacterial or fungal infections in the treatment area.
• Virus diseases (e.g. vaccinia, chickenpox).
• Secondary infections of the skin in the absence of appropriate anti-infective therapy.
• Known sensitivity to local anaesthetics.
• Corticosteroids have been shown to be teratogenic in animals. Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded. Therefore, SCHERIPROCT SUPPOSITORIES should not be used during pregnancy.
• Tuberculous or syphilitic processes in the area to be treated.

This product should not be used continuously for more than 7 days. If symptoms do not disappear quickly, discontinue treatment and consult your doctor. Certain anal disorders require specific treatment and a proctological examination. In case of bleeding, consult a doctor promptly.
In infants, long-term continuous therapy with topical corticosteroids should be avoided. Occlusion is not appropriate on the perineum. Adrenal suppression can occur, even without occlusion. There is a risk of developing skin atrophy following extensive therapy. The application of unusually large quantities of topical corticoids may result in the absorption of systemically active amounts of corticoid. Infections or secondarily infected dermatoses definitely require additional therapy with antibiotics or chemotherapeutic agents. This treatment can often be topical, but for heavy infections systemic antibacterial therapy may be necessary. If fungal infections are present, a topically active antimycotic should be applied.
The excipients in SCHERIPROCT SUPPOSITORIES may reduce the effectiveness of latex products such as condoms. Inadvertent contact of the preparation with the eyes should be avoided. Careful hand-washing after use is recommended.
Visual disturbance: Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

No interaction studies have been performed. Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects, including adrenal suppression. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case the patients should be monitored for systemic corticosteroid side effects.

Pregnancy
Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded. Therefore, SCHERIPROCT SUPPOSITORIES is contraindicated for use during pregnancy. There is insufficient data on the use of SCHERIPROCT SUPPOSITORIES in pregnant women. Studies in animals (mice and rats) have shown reproductive toxicity for prednisolone hexanoate. In general, the use of topical preparations containing glucocorticoids should be avoided during the first trimester of pregnancy. Epidemiological studies suggest that there could possibly be an increased risk of oral clefts among newborns of women who were treated with glucocorticoids during the first trimester of pregnancy.
Lactation
There is insufficient information on the excretion of prednisolone hexanoate and cinchocaine hydrochloride in human milk.

None known

There is a risk of developing skin atrophy following extensive therapy (more than 4 weeks). Allergic skin reactions may occur.
Eye disorders
Not known (frequency cannot be estimated from the available data): Vision, blurred (see also section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the u201c6.04 Adverse Drug Reaction Reporting Formu201d, found online under SAHPRAu2019s publications: https://www.sahpra.org.za/Publications/Index/8

In the case of accidental oral intake of the preparation (e.g. by swallowing several suppositories) mainly systemic effects of the local anaesthetic cinchocaine hydrochloride are to be expected, which, according to the dose, may manifest themselves as severe cardiovascular (depression to cessation of cardiac function) and CNS symptoms (convulsions; inhibition to arrest of respiratory function).